Doximity (DOCS) Stock Forecast & Price Target

Compare

862 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DOCS Analyst Ratings

Moderate Buy

8 Buy

8 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Doximity

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DOCS Stock 12 Month Forecast

Average Price Target

$67.73

▲(5.61% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Doximity in the last 3 months. The average price target is $67.73 with a high forecast of $80.00 and a low forecast of $57.00. The average price target represents a 5.61% change from the last price of $64.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","81":"$81","39.75":"$39.8","53.5":"$53.5","67.25":"$67.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$57.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,39.75,53.5,67.25,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.33,59.073846153846155,60.817692307692305,62.56153846153846,64.30538461538461,66.04923076923077,67.79307692307692,69.53692307692307,71.28076923076924,73.02461538461539,74.76846153846154,76.5123076923077,78.25615384615385,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.33,58.129999999999995,58.93,59.73,60.53,61.33,62.13,62.93,63.730000000000004,64.53,65.33,66.13000000000001,66.93,{"y":67.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.33,57.30461538461538,57.279230769230765,57.253846153846155,57.22846153846154,57.20307692307692,57.177692307692304,57.152307692307694,57.12692307692308,57.10153846153846,57.076153846153844,57.050769230769234,57.02538461538462,{"y":57,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.39,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.2,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.35,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.38,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$67.73

Lowest Price Target$57.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Cherny

Leerink Partners

$79

Buy

23.19%

Upside

Reiterated

08/15/25

Doximity's Strong Market Position and AI-Driven Growth Reinforce Buy RatingWe spent some time with DOCS management, including CFO Anna Bryson and VP of IR and RevOps Perry Gold as part of a set of meetings with investors in Boston. The meetings followed a decidedly positive FY1Q'26 results that showed widespread strength across the overall business/customer base. Our time with management confirmed our underlying view of DOCS' continually expanding moat, using a robust platform of solutions (discussed below) to drive expanding member engagement. And more engagement = better ROI for DOCS' core biopharma customer base. We continue to see robust profit growth/cash flow generation for DOCS and reiterate our Outperform rating.

Vikram Kesavabhotla

Robert W. Baird

$65→$75

Buy

16.95%

Upside

Reiterated

08/14/25

Doximity (DOCS) Gets a Buy from Robert W. BairdBaird analyst Vikram Kesavabhotla raised the price target on Doximity Inc (NYSE: DOCS) to $75.00 (from $65.00) while maintaining a Outperform rating.

Isla Carelynx

TR | OpenAI - 4o

$71

Buy

10.71%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

David Roman

Goldman Sachs

$50→$57

Hold

-11.12%

Downside

Reiterated

08/11/25

Analysts Conflicted on These Healthcare Names: Green Thumb Industries (Other OTC: GTBIF), Doximity (NYSE: DOCS) and BioLife Solutions (NASDAQ: BLFS)

Sean Wieland

Piper Sandler

$65→$69

Buy

7.59%

Upside

Reiterated

08/08/25

Doximity (DOCS) Gets a Buy from Piper Sandler

Brian Peterson

Raymond James

$65→$75

Buy

16.95%

Upside

Reiterated

08/08/25

Doximity price target raised to $75 from $65 at Raymond JamesDoximity price target raised to $75 from $65 at Raymond James

Alexei Gogolev

J.P. Morgan

$60→$62

Hold

-3.32%

Downside

Reiterated

08/08/25

J.P. Morgan Reaffirms Their Hold Rating on Doximity (DOCS)

Ryan MacDonald

Needham

$75

Buy

16.95%

Upside

Reiterated

08/08/25

Doximity's Strong Q1 and AI Innovations Drive Buy Rating Despite Growth Concerns

Craig Hettenbach

Morgan Stanley

$60→$62

Hold

-3.32%

Downside

Reiterated

08/08/25

Analysts Conflicted on These Healthcare Names: RegenXBio (NASDAQ: RGNX), Silence Therapeutics (NASDAQ: SLN) and Doximity (NYSE: DOCS)

Steven Valiquette

Mizuho Securities

$50→$59

Hold

-8.00%

Downside

Reiterated

08/08/25

Doximity (DOCS) Gets a Hold from Mizuho Securities

Stan Berenshteyn

Wells Fargo

$62→$65

Hold

1.36%

Upside

Reiterated

08/08/25

Doximity price target raised to $65 from $62 at Wells FargoDoximity price target raised to $65 from $62 at Wells Fargo

Elizabeth Anderson CFA

Evercore ISI

$70→$75

Buy

16.95%

Upside

Reiterated

08/08/25

Evercore ISI Sticks to Their Buy Rating for Doximity (DOCS)

Jailendra Singh

Truist Financial

$61→$62

Hold

-3.32%

Downside

Reiterated

08/08/25

Truist Financial Remains a Hold on Doximity (DOCS)

David Larsen

BTIG

$80

Buy

24.75%

Upside

Reiterated

08/08/25

Doximity (DOCS) Receives a Buy from BTIG

Richard Close

Canaccord Genuity

$50→$59

Hold

-8.00%

Downside

Reiterated

08/07/25

Doximity price target raised to $59 from $50 at CanaccordDoximity price target raised to $59 from $50 at Canaccord

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Cherny

Leerink Partners

$79

Buy

23.19%

Upside

Reiterated

08/15/25

Vikram Kesavabhotla

Robert W. Baird

$65→$75

Buy

16.95%

Upside

Reiterated

08/14/25

Doximity (DOCS) Gets a Buy from Robert W. BairdBaird analyst Vikram Kesavabhotla raised the price target on Doximity Inc (NYSE: DOCS) to $75.00 (from $65.00) while maintaining a Outperform rating.

Isla Carelynx

TR | OpenAI - 4o

$71

Buy

10.71%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

David Roman

Goldman Sachs

$50→$57

Hold

-11.12%

Downside

Reiterated

08/11/25

Analysts Conflicted on These Healthcare Names: Green Thumb Industries (Other OTC: GTBIF), Doximity (NYSE: DOCS) and BioLife Solutions (NASDAQ: BLFS)

Sean Wieland

Piper Sandler

$65→$69

Buy

7.59%

Upside

Reiterated

08/08/25

Doximity (DOCS) Gets a Buy from Piper Sandler

Brian Peterson

Raymond James

$65→$75

Buy

16.95%

Upside

Reiterated

08/08/25

Doximity price target raised to $75 from $65 at Raymond JamesDoximity price target raised to $75 from $65 at Raymond James

Alexei Gogolev

J.P. Morgan

$60→$62

Hold

-3.32%

Downside

Reiterated

08/08/25

J.P. Morgan Reaffirms Their Hold Rating on Doximity (DOCS)

Ryan MacDonald

Needham

$75

Buy

16.95%

Upside

Reiterated

08/08/25

Doximity's Strong Q1 and AI Innovations Drive Buy Rating Despite Growth Concerns

Craig Hettenbach

Morgan Stanley

$60→$62

Hold

-3.32%

Downside

Reiterated

08/08/25

Analysts Conflicted on These Healthcare Names: RegenXBio (NASDAQ: RGNX), Silence Therapeutics (NASDAQ: SLN) and Doximity (NYSE: DOCS)

Steven Valiquette

Mizuho Securities

$50→$59

Hold

-8.00%

Downside

Reiterated

08/08/25

Doximity (DOCS) Gets a Hold from Mizuho Securities

Stan Berenshteyn

Wells Fargo

$62→$65

Hold

1.36%

Upside

Reiterated

08/08/25

Doximity price target raised to $65 from $62 at Wells FargoDoximity price target raised to $65 from $62 at Wells Fargo

Elizabeth Anderson CFA

Evercore ISI

$70→$75

Buy

16.95%

Upside

Reiterated

08/08/25

Evercore ISI Sticks to Their Buy Rating for Doximity (DOCS)

Jailendra Singh

Truist Financial

$61→$62

Hold

-3.32%

Downside

Reiterated

08/08/25

Truist Financial Remains a Hold on Doximity (DOCS)

David Larsen

BTIG

$80

Buy

24.75%

Upside

Reiterated

08/08/25

Doximity (DOCS) Receives a Buy from BTIG

Richard Close

Canaccord Genuity

$50→$59

Hold

-8.00%

Downside

Reiterated

08/07/25

Doximity price target raised to $59 from $50 at CanaccordDoximity price target raised to $59 from $50 at Canaccord

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Doximity

1 Month

xxx

Success Rate

6/8 ratings generated profit

Average Return

+1.65%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +1.65% per trade.

3 Months

xxx

Success Rate

7/8 ratings generated profit

Average Return

+15.19%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +15.19% per trade.

1 Year

Isla CarelynxTR | OpenAI - 4o

Success Rate

7/8 ratings generated profit

Average Return

+14.14%

reiterated a buy rating 9 days ago

Copying Isla Carelynx's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +14.14% per trade.

2 Years

xxx

Success Rate

7/8 ratings generated profit

Average Return

+14.14%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +14.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DOCS Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DOCS has received 20 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. DOCS average Analyst price target in the past 3 months is 67.73.

Each month's total comprises the sum of three months' worth of ratings.

DOCS Financial Forecast

DOCS Earnings Forecast

Next quarter’s earnings estimate for DOCS is $0.37 with a range of $0.24 to $0.41. The previous quarter’s EPS was $0.36. DOCS beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.06% of the time in the same period. In the last calendar year DOCS has Outperformed its overall industry.

DOCS Sales Forecast

Next quarter’s sales forecast for DOCS is $156.84M with a range of $149.60M to $158.00M. The previous quarter’s sales results were $145.91M. DOCS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.27% of the time in the same period. In the last calendar year DOCS has Outperformed its overall industry.

DOCS Stock Forecast FAQ

What is DOCS’s average 12-month price target, according to analysts?

Based on analyst ratings, Doximity’s 12-month average price target is 67.73.

What is DOCS’s upside potential, based on the analysts’ average price target?

Doximity has 5.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DOCS a Buy, Sell or Hold?

Doximity has a consensus rating of Moderate Buy which is based on 8 buy ratings, 8 hold ratings and 0 sell ratings.

What is Doximity’s price target?

The average price target for Doximity is 67.73. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $57.00. The average price target represents 5.61% Increase from the current price of $64.13.

What do analysts say about Doximity?

Doximity’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of DOCS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Doximity (DOCS) Stock Forecast & Price Target

DOCS Analyst Ratings

DOCS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Doximity

DOCS Analyst Recommendation Trends

DOCS Financial Forecast

DOCS Earnings Forecast

DOCS Sales Forecast

DOCS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts